Momenta Phama (MNTA) Misses Q2 EPS by 50c, Revenues Miss

Momenta Phama (NASDAQ: MNTA) reported Q2 EPS of ($0.91), $0.50 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $13.03 million versus the consensus estimate of $21.05 million.

“The strategic review of our business announced earlier this year is progressing and we are actively evaluating options for our biosimilars business. We expect to complete this review and announce an outcome in the coming weeks,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “Our novel drug candidates for rare autoimmune diseases continue to advance. We remain on track to initiate two Phase 2 proof of concept studies of M281 in the fourth quarter of 2018 and a Phase 1/2 proof of concept study of M254, our hyper-sialylated IVIg candidate, in late 2018 or early 2019, pending regulatory feedback.”

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c